Interferon-alpha plus ribavirin and amantadine in patients with post-transplant hepatitis C: Results of a pilot study

P. Andreone, A. Gramenzi, C. Cursaro, M. Biselli, L. Di Giammarino, G. L. Grazi, E. Jovine, A. D'Errico, S. Galli, A. Mazziotti, A. Cavallari, M. Bernardi

Research output: Contribution to journalArticlepeer-review


Background. Recurrence of hepatitis C after liver transplantation is almost constant and may lead to graft loss. The results of treatment with interferon and/or other agents have been controversial. Aims. To evaluate the efficacy and safety of combination therapy with interferon-α2b (3 MU, 3 times weekly), ribavirin (600 mg daily) and amantadine (100 mg daily) in post-transplant hepatitis C. Patients and Methods. Enrolled in the study were 9 liver transplant recipients with histologically proven recurrent hepatitis C. Patients were treated for 12 months and followed up for 6 months after treatment. Results. Treatment was not tolerated: only one patient completed the planned course, two stopped therapy within the first 3 months and 6 needed a change. However, mean alanine aminotransferase levels significantly decreased during treatment and were significantly lower than baseline at the end of follow-up. One patient out of 9 (11%) achieved a biochemical and virological sustained response. Control liver biopsy showed improvement in 2/7 patients, no change in 3 and worsening in 2. Conclusions. In recurrent post-transplant hepatitis C, antiviral treatment with interferon, ribavirin and amantadine seems to be poorly tolerated. However, further studies are needed before expressing any conclusion on this potentially important option.

Original languageEnglish
Pages (from-to)693-698
Number of pages6
JournalDigestive and Liver Disease
Issue number8
Publication statusPublished - 2001


  • Amantadine
  • Hepatitis C
  • Interferon
  • Liver transplant
  • Ribavirin

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Interferon-alpha plus ribavirin and amantadine in patients with post-transplant hepatitis C: Results of a pilot study'. Together they form a unique fingerprint.

Cite this